Toggle navigation
Home
Search
Services
Blog
Contact
About
Rational Design of Neuropeptide Y Therapeutics
Salon, John A.
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States
Search 7 grants from John Salon
Search grants from Synaptic Pharmaceutical Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Molecular Determinants of Cross-Reactive Antibody Response to Influenza in Humans
Studying metabolic stress signaling in renal cancer
Synaptic integration in the deep cerebellar nuclei
Hereditary Hemochromatosis
Mast Cell-Specific Regulation of IL-4 Gene Expression
Recently added grants:
Exploiting Natural Genetic and Organismic Variation to Identify the DNA Motifs Regulating Transcription
Fundamental Studies of RNA Conformational Thermodynamics
Understanding human lysosomal-autophagic dysfunction in CLN6 with IPSC-derived neural cells
Transfusion Biology and Cellular Therapies
Rationale for the Pediatric Hematology and Transfusion Medicine Multidisciplinary Research Training Award (PHTMMRT) at Children?s National
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS031843-03
Application #
2269799
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (13))
Project Start
1994-09-01
Project End
1996-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652
Related projects
NIH 1995
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
NIH 1994
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
Comments
Be the first to comment on this grant